4Kan LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm, 2002, 59 : 33-41.
5Laima Taraseviciene - Stewart, lvor S. Douglas, Patrick S. Nana -Sinkam, et al. lund copd symposium:tissue remodeling and repair mechanisms in chronic obstructive pulmonary disease: Is Alveolar Destruction and Emphysema in Chronic Obstructive Pulmonary Disease an Immune Disease? Proceedings of the ATS, Nov 2006,3 : 687-690.
6Chen KY, Ko SC, Hsueh PR, et al. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest, 2001,120 ( 1 ) : 177-184.
7Alberto Papi, Fabrizio Luppi, Francesca Franeo,et al. Session II. pathophysiolgy leading to priority outcomes:pathophysiology of Exacerbations of chronic obstructive pulmonary disease. Proceedings of the ATS ,2006,3 : 245-251.
8Chen Y K, Ko S C, Hsueh P R, et al. Pulmonary fungal infection:em phasis on microbiological spectra, patient outcome, and prognostic fac tors [J] . Chest, 2001, 120 (1) : 177-184.
9Gegory R K, Powles R L, Treleaven J G, et ol. Systemic candidiasis with candida vasculitis due to Candida lruzci in a patient with acute myeloid leukacmia [J] . Bone Marrow Transplant, 1999, 23 : 103.
10Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit [J] . Am J Health Syst Pharm, 2002, 59 : 33-41.
